论文部分内容阅读
目的分析启东市人民医院2016年活血化瘀类中成药用药情况,为临床安全用药提供指导。方法收集启东市人民医院2016年活血化瘀类中成药的出库数据以及上报的不良反应报告。对药品种类、销售金额、用药频度(DDDs)、日均费用(DDC)、排序比(B/A)和不良反应的类型、科室分布进行统计、排序和分析。结果 2016年启东市人民医院活血化瘀类中成药分布科室以心内科、神经内一科和神经内二科为主,分别占26.11%、16.91%、15.13%。活血化瘀类中成药销售额最高的是舒血宁注射液,DDDs最高的是血府逐瘀片,DDC最高的是丹红注射液,大部分药品的B/A值偏离1,表明市场份额和用药选择一致性较差。34例(2.52%)发生不良反应,注射剂有27例,非注射剂7例。结论启东市人民医院活血化瘀类中成药临床应用仍存在一定的不合理情况,需要采取一些干预措施。
Objective To analyze the use of proprietary Chinese medicines in Qudong Dong People’s Hospital in 2016 to provide guidance for clinical safe medication. Methods The Qudong People’s Hospital in 2016 out of the library data of traditional Chinese medicine and reporting of adverse reactions reported. The types of drugs, the amount of sales, the frequency of medication DDDs, DDC, B / A and the type of adverse reactions, department distribution statistics, sorting and analysis. Results In 2016, the distribution of proprietary Chinese medicines in Qidong People’s Hospital was mainly in the departments of cardiology, neurology and neurology, accounting for 26.11%, 16.91% and 15.13% respectively. Xuexuening Injection has the highest sales of proprietary Chinese medicines in blood circulation and blood stasis syndrome. The highest DDDs are Xuefu Zhuyu tablets, and the highest DDC is Danhong Injection. The B / A value of most medicines deviates from 1, indicating the market share Consistency and drug choice less well. Adverse reactions occurred in 34 cases (2.52%) with 27 injections and 7 non-injections. Conclusion There are still some unreasonable situations in the clinical application of proprietary Chinese medicines of Qidong People’s Hospital in promoting blood circulation and removing blood stasis. Some interventions are needed.